Lapatinib in metastatic breast cancer

Women's Health

Volumn 5, Issue 6, 2009, Pages 603-612

  Frenel, J S ^a   Bourbouloux, E ^a   Berton Rigaud, D ^a   Sadot Lebouvier, S ^a   Zanetti, A ^a   Campone, M ^a,b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSERM   (France)

Author keywords

Breast cancer; EGF receptor; HER2; Lapatinib; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

ANTHRACYCLINE; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GLYCOPROTEIN P; LAPATINIB; LETROZOLE; LOPERAMIDE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN BCL 2; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; ENZYME ACTIVITY; FATIGUE; FOOD DRUG INTERACTION; GENE AMPLIFICATION; GRAPEFRUIT; HAIR DISEASE; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IC 50; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; PRURITUS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INFECTION; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; NEOPLASM METASTASIS; QUINAZOLINES;

EID: 70549102060     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.54     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP: Multiple-treatments meta- analysis of chemotherapy and targeted therapies in advanced breast cancer. J. Natl Cancer Inst. 100, 1780-1791 (2008).
3. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/n gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105 (2002).
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/n oncogene. Science 235, 177-182 (1987).
5. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
6. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002). (Pubitemid 34111379)
7. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
8. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
10. Nagata Y, Lan KH, Zhou X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004). (Pubitemid 39485684)
11. Bramwell VH, Doig GS, Tuck AB et al.: Serial measurement of serum extracellular domain of HER2 (ECD/HER2) has prognostic value in metastatic breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1), (2006).
12. Lu Y, Zi X, Pollak M: Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin®) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341 (2004).
13. Price-Schiavi SA, Jepson S, Li P et al.: Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99, 783-791 (2002). (Pubitemid 34575694)
14. Valabrega G, Montemurro F, Sarotto I et al.: TGF-a expression impairs Trastuzumab- induced HER2 downregulation. Oncogene 24, 3002-3010 (2005). (Pubitemid 40675531)
15. Spector NL, Xia W, Burris H 3rd et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23, 2502-2512 (2005).
16. Lackey KE: Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem. 6, 435-460 (2006).
17. Rusnak DW, Lackey K, Affleck K et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85-94 (2001).
18. Konecny GE, Pegram MD, Venkatesan N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
19. Burris HA 3rd, Hurwitz HI, Dees EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305-5313 (2005).
20. Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A: Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 67, 421-426 (2009).
21. Polli JW, Humphreys JE, Harmon KA et al.: The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}-6-[5-({[2- (methylsulfonyl)ethy l] amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 36, 695-701 (2008).
22. Koch KM, Reddy NJ, Cohen RB et al.: Effects of food on the relative bioavailability of lapatinib in cancer patients. J. Clin. Oncol. 27, 1191-1196 (2009).
23. Blackwell KL, Pegram MD, Tan-Chiu E et al.: Single-agent lapatinib for HER2- overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. (2009) (Epub ahead of print).
24. Burstein HJ, Storniolo AM, Franco S et al.: A Phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 19, 1068-1074 (2008). (Pubitemid 351796331)
25. Iwata H, Toi M, Fujiwara Y et al.: Phase II study of lapatinib in patients with advanced or metastatic breast cancer. Presented at: The 29th Annual CTCR-AACR San Antonio Breast Cancer Symposium. (2006).
26. Chu QS, Schwartz G, de Bono J et al.: Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J. Clin. Oncol. 25, 3753-3758 (2007).
27. Geyer CE, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006). •• Phase III study demonstrating the superiority of lapatinib plus capecitabine to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane and trastuzumab.
28. Cameron D, Casey M, Press M et al.: A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112, 533-543 (2008). •• This update of the Phase III study of Geyer confirms the survival benefit of the combination of lapatinib and capecitabine.
29. Di Leo A, Gomez HL, Aziz Z et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544-5552 (2008).
30. Crown JP, Burris HA 3rd, Boyle F et al.: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 112, 317-325 (2008).
31. Lacouture ME, Laabs SM, Koehler M et al.: Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 114, 485-493 (2009).
32. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008).
33. Bendell JC, Domchek SM, Burstein HJ et al.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977 (2003).
34. Clayton AJ, Danson S, Jolly S et al.: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91, 639-643 (2004).
35. Lin NU, Winer EP: Brain metastases: the HER2 paradigm. Clin. Cancer Res. 13, 1648-1655 (2007).
36. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15, 219-225 (2006).
37. Yau T, Swanton C, Chua S et al.: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 45, 196-201 (2006).
38. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P: Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab- based therapy. Ann. Oncol. 16, 1772-1777 (2005).
39. Pestalozzi BC, Zahrieh D, Price KN et al.: Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 17, 935-944 (2006).
40. Lin NU, Carey LA, Liu MC et al.: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993-1999 (2008).
41. Lin NU, Dieras V, Paul D et al.: Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009).
42. Gomez HL, Doval DC, Chavez MA et al.: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999-3005 (2008).
43. Johnston S, Pegram M, Press M et al.: Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial. Presented at: The 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium. (2008) (Abstract 46).
44. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24, 6213-6221 (2005).
45. Storniolo AM, Pegram MD, Overmoyer B et al.: Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 26, 3317-3323 (2008).
46. Storniolo AM, Koehler M, Preston A et al.: Cardiac safety in patients with metastatic breast cancer treated with lapatinib and trastuzumab. J. Clin. Oncol. 25(6S), 514 (2008).
47. O'Shaughnessy J, Blackwell KL, Burstein H, et al.: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26(15S), 1015 (2008).
48. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol. 34, 499-504 (1995).
49. Johnston S, Trudeau M, Kaufman B et al.: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 26, 1066-1072 (2008).
50. Press MF, Finn RS, Cameron D et al.: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin. Cancer Res. 14, 7861-7870 (2008).
51. Ongoing clinical trials. www.clinicaltrials.gov